Xenoport shares get a lift from positive drug trial results(0)
Xenoport, the Santa Clara biopharmaceutical, reported positive preliminary results today from a Phase 2 clinical trial of its treatment for patients with spasticity related to spinal cord injury. Patients given twice-daily doses showed “statistically significant improvement” compared to those receiving a placebo.
The company also said the drug candidate, arbaclofen placarbil, was Read the rest of this entry »
Subscribe via RSS all feeds